×

British cancer drug developer Ellipses Pharma consider London listing

By Thomson Reuters Nov 18, 2026 | 3:18 AM

Nov 18 (Reuters) – British cancer drug developer Ellipses Pharma on Wednesday said it was exploring a ​London listing through a ‌deal with  special purpose acquisition company Wolfram Resources.

• Established in 2017, Ellipses Pharma’s pipeline includes trials for drugs to ‌treat ​non-small cell lung ⁠cancer and breast ⁠cancer

• The company plans to list its shares on the London bourse following a reverse takeover ​by shell company Wolfram Resources, whose terms are yet ⁠to be agreed

• The ⁠floatation will provide a ​much-needed boost to the UK’s market ​which has seen an exodus ‌from companies eyeing higher valuations in markets like the United States

• Ellipses Pharma said it ⁠is targeting completing the transaction by early 2027

• The firm also expects an ⁠equity fundraise ‌in conjunction with ⁠the deal

• Listing through a ​reverse ‌takeover process will enable ​the company ⁠to raise additional capital from public company investors, founder and chair Chris Evans said

(Reporting by Simone Lobo in Bengaluru; Editing by ​Nivedita Bhattacharjee)